{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:04:20Z","timestamp":1777899860333,"version":"3.51.4"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,5,9]],"date-time":"2015-05-09T00:00:00Z","timestamp":1431129600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s12072-015-9633-1","type":"journal-article","created":{"date-parts":[[2015,5,8]],"date-time":"2015-05-08T06:21:33Z","timestamp":1431066093000},"page":"471-479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease"],"prefix":"10.1007","volume":"9","author":[{"given":"Sahar Mohamed","family":"El-Haggar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek Mohamed","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,9]]},"reference":[{"key":"9633_CR1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11894-009-0008-4","volume":"11","author":"VL Misra","year":"2009","unstructured":"Misra VL, Khashab M, Chalasani N. Nonalcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep 2009;11:50\u201355","journal-title":"Curr Gastroenterol Rep"},{"key":"9633_CR2","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1053\/jhep.2002.32483","volume":"35","author":"ZM Younossi","year":"2002","unstructured":"Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002;35:743\u2013752","journal-title":"Hepatology"},{"key":"9633_CR3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2001-12926","volume":"21","author":"Y Falck-Ytter","year":"2001","unstructured":"Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17\u201326","journal-title":"Semin Liver Dis"},{"key":"9633_CR4","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1053\/j.gastro.2007.03.055","volume":"132","author":"S Parekh","year":"2007","unstructured":"Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007;132:2191\u20132207","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"9633_CR5","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1046\/j.1440-1746.17.s1.10.x","volume":"17","author":"P Angulo","year":"2002","unstructured":"Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002;17(Suppl):S186\u2013S190","journal-title":"J Gastroenterol Hepatol"},{"key":"9633_CR6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.7326\/0003-4819-132-2-200001180-00004","volume":"132","author":"S Bellentani","year":"2000","unstructured":"Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112\u2013117","journal-title":"Ann Intern Med"},{"key":"9633_CR7","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1210\/jc.2004-1024","volume":"90","author":"F Angelico","year":"2005","unstructured":"Angelico F, Del Ben M, Conti R, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005;90:1578\u20131582","journal-title":"J Clin Endocrinol Metab"},{"key":"9633_CR8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1467-789X.2009.00594.x","volume":"10","author":"MA Edens","year":"2009","unstructured":"Edens MA, Kuipers F, Stolk RP. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes Rev 2009;10:412\u2013419","journal-title":"Obes Rev"},{"key":"9633_CR9","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/01.mog.0000182863.96421.47","volume":"21","author":"S Choi","year":"2005","unstructured":"Choi S, Diehl AM. Role of inflammation in nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2005;21:702\u2013707","journal-title":"Curr Opin Gastroenterol"},{"key":"9633_CR10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/gut.2006.106021","volume":"56","author":"N Assy","year":"2007","unstructured":"Assy N, Hussein O, Abassi Z. Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut 2007;56:443\u2013444","journal-title":"Gut"},{"key":"9633_CR11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1440-1681.2007.04547.x","volume":"34","author":"XZ Hong","year":"2007","unstructured":"Hong XZ, Li LD, Wu LM. Effects of fenofibrate and Xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol 2007;34:27\u201335","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"9633_CR12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.cld.2004.04.012","volume":"8","author":"AM Diehl","year":"2004","unstructured":"Diehl AM. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:619\u2013638","journal-title":"Clin Liver Dis"},{"key":"9633_CR13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.bbalip.2011.10.016","volume":"1821","author":"A Tailleux","year":"2012","unstructured":"Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta 2012;1821:809\u2013818","journal-title":"Biochim Biophys Acta"},{"key":"9633_CR14","doi-asserted-by":"crossref","first-page":"805","DOI":"10.5414\/CP201735","volume":"50","author":"L Buldak","year":"2012","unstructured":"Buldak L, Dulawa-Buldak A, Labuzek K, Okopien B. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose. Int J Clin Pharmacol Ther 2012;50:805\u2013813","journal-title":"Int J Clin Pharmacol Ther"},{"key":"9633_CR15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2010.10.023","volume":"214","author":"KK Koh","year":"2011","unstructured":"Koh KK, Quon MJ, Lim S, et al. Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia. Atherosclerosis 2011;214:144\u2013147","journal-title":"Atherosclerosis"},{"key":"9633_CR16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.dld.2007.10.002","volume":"40","author":"C Fern\u00e1ndez-Miranda","year":"2008","unstructured":"Fern\u00e1ndez-Miranda C, P\u00e9rez-Carreras M, Colina F, L\u00f3pez-Alonso G, Vargas C, Sol\u00eds-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2008;40:200\u2013205","journal-title":"Dig Liver Dis"},{"key":"9633_CR17","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1126\/science.271.5249.665","volume":"271","author":"GS Hotamisligil","year":"1996","unstructured":"Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996;271:665\u2013668","journal-title":"Science"},{"key":"9633_CR18","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1111\/j.1572-0241.2004.40220.x","volume":"99","author":"SK Satapathy","year":"2004","unstructured":"Satapathy SK, Garg S, Chauhan R, et al. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:1946\u20131952","journal-title":"Am J Gastroenterol"},{"key":"9633_CR19","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1185\/030079906X104696","volume":"22","author":"VG Athyros","year":"2006","unstructured":"Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006;22:873\u2013883","journal-title":"Curr Med Res Opin"},{"key":"9633_CR20","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00125-007-0698-9","volume":"50","author":"M Bajaj","year":"2007","unstructured":"Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 2007;50:1723\u20131731","journal-title":"Diabetologia"},{"issue":"2","key":"9633_CR21","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s12072-008-9058-1","volume":"2","author":"YM Lee","year":"2008","unstructured":"Lee YM, Sutedja DS, Wai CT, et al. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2008;2(2):196\u2013201","journal-title":"Hepatol Int"},{"key":"9633_CR22","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","volume":"376","author":"VG Athyros","year":"2010","unstructured":"Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916\u20131922","journal-title":"Lancet"},{"issue":"6","key":"9633_CR23","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","volume":"55","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55(6):2005\u20132023","journal-title":"Hepatology"},{"issue":"3","key":"9633_CR24","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/gast.2002.35354","volume":"123","author":"S Saadeh","year":"2002","unstructured":"Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gasteroenterology 2002;123(3):745\u2013750","journal-title":"Gasteroenterology"},{"key":"9633_CR25","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499\u2013502","journal-title":"Clin Chem"},{"issue":"7","key":"9633_CR26","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412\u2013419","journal-title":"Diabetologia"},{"key":"9633_CR27","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1478-3231.2008.01784.x","volume":"28","author":"J Fung","year":"2008","unstructured":"Fung J, Lai CL, Fong DY, et al. Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver Int 2008;28:1408\u20131416","journal-title":"Liver Int"},{"key":"9633_CR28","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","volume":"98","author":"B Staels","year":"1998","unstructured":"Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088\u20132093","journal-title":"Circulation"},{"issue":"1","key":"9633_CR29","first-page":"39","volume":"16","author":"EF Georgescu","year":"2007","unstructured":"Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gasterointest Liver Dis 2007;16(1):39\u201346","journal-title":"J Gasterointest Liver Dis"},{"issue":"2","key":"9633_CR30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12055-009-0042-8","volume":"25","author":"S Surjit","year":"2009","unstructured":"Surjit S, Harbinder S, Arvind K, Vinod K, Gurjit S. Effects of cilostazole and pentoxifylline on claudication distance and lipid profile in patients with occlusive peripheral arterial disease: a comparative trial. Indian J Thorac Cardiovasc Surg 2009;25(2):45\u201348","journal-title":"Indian J Thorac Cardiovasc Surg"},{"key":"9633_CR31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-2007-1007110","volume":"19","author":"CJ McClain","year":"1999","unstructured":"McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis 1999;19:205\u2013219","journal-title":"Semin Liver Dis"},{"key":"9633_CR32","first-page":"211","volume":"4","author":"S Fatani","year":"2011","unstructured":"Fatani S, Itua I, Clark P, Wong C, Naderali EK. The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage. Int J Gen Med 2011;4:211\u2013219","journal-title":"Int J Gen Med"},{"key":"9633_CR33","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0006-291X(88)81271-3","volume":"155","author":"RM Strieter","year":"1988","unstructured":"Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha by pentoxifylline. Biochem Biophys Res Commun 1988;155:1230\u20131236","journal-title":"Biochem Biophys Res Commun"},{"key":"9633_CR34","first-page":"262","volume":"83","author":"P Neuner","year":"1994","unstructured":"Neuner P, Klosner G, Schauer E, et al. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 1994;83:262\u2013267","journal-title":"Immunology"},{"key":"9633_CR35","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/j.1572-0241.2004.40064.x","volume":"99","author":"LA Adams","year":"2004","unstructured":"Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in non alcoholic steatohepatitis. Am J Gastroenterol 2004;99:2365\u20132368","journal-title":"Am J Gastroenterol"},{"key":"9633_CR36","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM200011163432007","volume":"343","author":"H Tilg","year":"2000","unstructured":"Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467\u20131476","journal-title":"N Engl J Med"},{"issue":"10","key":"9633_CR37","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1007\/s10620-006-9723-y","volume":"52","author":"DG Duman","year":"2007","unstructured":"Duman DG, Ozdemir F, Birben E, et al. Effects of pentoxifylline on TNF-alpha production by peripheral blood mononuclear cells in patients with nonalcoholic steatohepatitis. Dig Dis Sci 2007;52(10):2520\u20132524","journal-title":"Dig Dis Sci"},{"key":"9633_CR38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/00365520601058395","volume":"42","author":"MC Diakou","year":"2007","unstructured":"Diakou MC, Liberopoulos EN, Mikhailidis DP, Tsianos EV, Burroughs AK, Elisaf MS. Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. Scand J Gastroenterol 2007;42:139\u2013147","journal-title":"Scand J Gastroenterol"},{"key":"9633_CR39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.atherosclerosis.2011.11.018","volume":"220","author":"KK Koh","year":"2012","unstructured":"Koh KK, Quon MJ, Shin KC, et al. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. Atherosclerosis 2012;220:537\u2013544","journal-title":"Atherosclerosis"},{"key":"9633_CR40","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1177\/147323001103900531","volume":"39","author":"XM Li","year":"2011","unstructured":"Li XM, Li Y, Zhang NN, Xie YH, Shi YQ. Combination therapy with metformin and fenofibrate for insulin resistance in obesity. J Int Med Res 2011;39:1876\u20131882","journal-title":"J Int Med Res"},{"key":"9633_CR41","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jhep.2004.06.030","volume":"41","author":"SW Koppe","year":"2004","unstructured":"Koppe SW, Sahai A, Malladi P, Whitington PF, Green RM. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatol 2004;41:592\u2013598","journal-title":"J Hepatol"},{"key":"9633_CR42","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1440-1746.2006.04756.x","volume":"22","author":"SK Satapathy","year":"2007","unstructured":"Satapathy SK, Garq S, Sakhuja P, et al. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007;22:634\u2013638","journal-title":"J Gastroenterol Hepatol"},{"key":"9633_CR43","doi-asserted-by":"crossref","first-page":"403","DOI":"10.12968\/jowc.2010.19.9.78235","volume":"19","author":"HE Douglas","year":"2010","unstructured":"Douglas HE. TGF-\u00df in wound healing: a review. J Wound Care 2010;19:403\u2013406","journal-title":"J Wound Care"},{"key":"9633_CR44","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.cld.2009.07.003","volume":"13","author":"WK Syn","year":"2009","unstructured":"Syn WK, Choi SS, Diehl AM. Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin Liver Dis 2009;13:565\u2013580","journal-title":"Clin Liver Dis"},{"key":"9633_CR45","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1479-5876-6-72","volume":"6","author":"G Tarantino","year":"2008","unstructured":"Tarantino G, Conca P, Riccio A, et al. Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? J Transl Med 2008;6:72","journal-title":"J Transl Med"},{"issue":"7","key":"9633_CR46","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0009-9120(99)00058-2","volume":"32","author":"RG Cameron","year":"1999","unstructured":"Cameron RG, Neuman MG. Novel morphologic findings in alcoholic liver disease. Clin Biochem 1999;32(7):579\u2013584","journal-title":"Clin Biochem"},{"key":"9633_CR47","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0168-8278(03)00360-X","volume":"39","author":"P St\u00e4rkel","year":"2003","unstructured":"St\u00e4rkel P, Sempoux C, Leclercq I, et al. Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J Hepatol 2003;39:538\u2013546","journal-title":"J Hepatol"},{"issue":"2","key":"9633_CR48","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12291-011-0121-7","volume":"26","author":"SK Das","year":"2011","unstructured":"Das SK, Balakrishnan V. Role of cytokines in the pathogenesis of non-alcoholic fatty liver disease. Indian J Clin Biochem 2011;26(2):202\u2013209","journal-title":"Indian J Clin Biochem"},{"issue":"6","key":"9633_CR49","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00535-013-0910-2","volume":"49","author":"K Matsuzaki","year":"2014","unstructured":"Matsuzaki K, Seki T, Okazaki K. TGF-beta signal shifting between tumor suppression and fibro-carcinogenesis in human chronic liver diseases. J Gastroenterol 2014;49(6):971\u2013981","journal-title":"J Gastroenterol"},{"issue":"3","key":"9633_CR50","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1258\/ebm.2009.009218","volume":"235","author":"L Li","year":"2010","unstructured":"Li L, Emmett N, Mann D, Zhao X. Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-\u03baB and transforming growth factor-\u03b21\/Smad3 in diabetic nephropathy. Exp Biol Med (Maywood) 2010;235(3):383\u2013391","journal-title":"Exp Biol Med (Maywood)"},{"issue":"12","key":"9633_CR51","first-page":"914","volume":"21","author":"C Xie","year":"2013","unstructured":"Xie C, Li L, Xu YP, Zhu YY, Jiang JJ. Anti-fibrosis effects of fenofibrate in mice with hepatic fibrosis. Zhonghua Gan Zang Bing Za Zhi 2013;21(12):914\u2013919","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"2","key":"9633_CR52","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/gut.50.2.241","volume":"50","author":"C Raetsch","year":"2002","unstructured":"Raetsch C, Jia JD, Boigk G, Bauer M, Hahn EG, Riecken E-O, et al. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut 2002;50(2):241\u2013247","journal-title":"Gut"},{"key":"9633_CR53","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0162-3109(95)00048-8","volume":"31","author":"TC Peterson","year":"1996","unstructured":"Peterson TC, Neumeister M. Effect of pentoxifylline in rat and swine models of hepatic fibrosis: role of fibroproliferation in its mechanism. Immunopharmacology 1996;31:183\u2013193","journal-title":"Immunopharmacology."},{"issue":"1","key":"9633_CR54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-2796.1997.00170.x","volume":"242","author":"JRE Fraser","year":"1997","unstructured":"Fraser JRE, Laurent TC, Laurent UBG. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 1997;242(1):27\u201333","journal-title":"J Intern Med"},{"issue":"2","key":"9633_CR55","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1665-2681(19)31784-3","volume":"8","author":"F Vizzutti","year":"2009","unstructured":"Vizzutti F, Arena U, Nobili V, et al. Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease. Ann Hepatol 2009;8(2):89\u201394","journal-title":"Ann Hepatol"},{"issue":"3","key":"9633_CR56","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ajg.2009.09.001","volume":"10","author":"MA Amin","year":"2009","unstructured":"Amin MA, Sabry D, Kassem M, Amin A. Effect of pentoxifylline on serum hyaluronic acid in patients with non-alcoholic fatty liver disease. Arab J Gastroenterol 2009;10(3):102\u2013105","journal-title":"Arab J Gastroenterol"},{"key":"9633_CR57","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0006-2952(95)02173-6","volume":"51","author":"C Windmeier","year":"1996","unstructured":"Windmeier C, Gressner AM. Effect of pentoxifylline on the fibrogenic functions of cultured rat liver fat-storing cells and myofibroblasts. Biochem Pharmacol 1996;51:577\u2013584","journal-title":"Biochem Pharmacol"},{"key":"9633_CR58","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hep.510260210","volume":"26","author":"AM Preaux","year":"1997","unstructured":"Preaux AM, Mallat A, Rosenbaum J, Zafrani ES, Mavier P. Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells. Hepatology 1997;26:315\u2013322","journal-title":"Hepatology"},{"key":"9633_CR59","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-4419-1241-1_10","volume":"662","author":"K Kondo","year":"2010","unstructured":"Kondo K, Sugioka T, Tsukada K, Aizawa M, Takizawa M, Shimizu K, et al. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice. Adv Exp Med Biol 2010;662:77\u201382","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"9633_CR60","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1478-3231.2006.01265.x","volume":"26","author":"Y Harano","year":"2006","unstructured":"Harano Y, Yasui K, Toyama T, Nakajima T, Mitsuyoshi H, Mimani M, et al. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int 2006;26(5):613\u2013620","journal-title":"Liver Int"},{"key":"9633_CR61","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/hep.1840210429","volume":"21","author":"K Kozaki","year":"1995","unstructured":"Kozaki K, Egawa H, Bermudez L, Keefe EB, So SK, Esquivel DO. Effects of pentoxifylline pretreatment on Kupffer cells in rat liver transplantation. Hepatology 1995;21:1079\u20131082","journal-title":"Hepatology"},{"issue":"6","key":"9633_CR62","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/000331979204300602","volume":"43","author":"PL Sonkin","year":"1992","unstructured":"Sonkin PL, Chen LE, Seaber AV, Hatchell DL. Vasodilator action of pentoxifylline on microcirculation of rat cremaster muscle. Angiology 1992;43(6):462\u2013469","journal-title":"Angiology"},{"issue":"3","key":"9633_CR63","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00005373-199703000-00010","volume":"42","author":"P Wang","year":"1997","unstructured":"Wang P, Ba ZF, Chaudry IH. Pentoxifylline maintains hepatocellular function and improves cardiac performance during early sepsis. J Trauma 1997;42(3):429\u2013435","journal-title":"J Trauma"},{"key":"9633_CR64","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1007\/BF01308607","volume":"38","author":"F Froehlich","year":"1993","unstructured":"Froehlich F, Lamy O, Fried M, Gonvers JJ. Practice and complications of liver biopsy. Results of a nation wide survey in Switzerland. Dig Dis Sci 1993;38:1480\u20131484","journal-title":"Dig Dis Sci"},{"key":"9633_CR65","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1478-3231.2008.01802.x","volume":"29","author":"P Marcellin","year":"2009","unstructured":"Marcellin P, Ziol M, Bedossa P, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009;29:242\u2013247","journal-title":"Liver Int."},{"key":"9633_CR66","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2893.2010.01355.x","volume":"18","author":"J Fung","year":"2011","unstructured":"Fung J, Lai CL, Seto WK, Wong DK, Yuen MF. Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. J Viral Hepat 2011;18:738\u2013744","journal-title":"J Viral Hepat"},{"issue":"2","key":"9633_CR67","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbrc.2004.09.110","volume":"324","author":"T Toyama","year":"2004","unstructured":"Toyama T, Nakamura H, Harano Y, et al. PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. Biochem Biophys Res Commun 2004;324(2):697\u2013704","journal-title":"Biochem Biophys Res Commun"},{"key":"9633_CR68","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/hep.24544","volume":"54","author":"CO Zein","year":"2011","unstructured":"Zein CO, Yerian LM, Gogate P, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011;54:1610\u20131619","journal-title":"Hepatology"},{"key":"9633_CR69","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/hep.20170","volume":"39","author":"E Ip","year":"2004","unstructured":"Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 2004;39:1286\u20131296","journal-title":"Hepatology"},{"issue":"5","key":"9633_CR70","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1440-1746.2008.05749.x","volume":"24","author":"K Toda","year":"2009","unstructured":"Toda K, Kumagai N, Kaneko F, Tsunematsu S, Tsuchimoto K, Saito H, et al. Pentoxifylline prevents pig serum-induced rat liver fibrosis by inhibiting interleukin-6 production. J Gastroenterol Hepatol 2009;24(5):860\u2013865","journal-title":"J Gastroenterol Hepatol"},{"issue":"5 Pt 1","key":"9633_CR71","first-page":"G1094","volume":"273","author":"KS Lee","year":"1997","unstructured":"Lee KS, Cottam HB, Houglum K, Wasson DB, Carson D, Chojkier M. Pentoxifylline blocks hepatic stellate cell activation independently of phosphodiesterase inhibitory activity. Am J Physiol 1997;273(5 Pt 1):G1094\u2013G1100","journal-title":"Am J Physiol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9633-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-015-9633-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9633-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T21:16:23Z","timestamp":1748380583000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-015-9633-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,9]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["9633"],"URL":"https:\/\/doi.org\/10.1007\/s12072-015-9633-1","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,9]]}}}